Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 05 May 2023
In order to treat osteosarcoma, a bone cancer that primarily affects children, recent research has discovered a potential therapeutic target and created a novel delivery system.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
Bayer is transforming pharmaceutical research into women's health
2.
The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.
3.
Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds
4.
Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study
5.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
1.
Preventing Functional Iron Deficiency in High-Risk Populations
2.
Interpreting Iron Studies: What Your Blood Results Really Mean
3.
Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer
4.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
5.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge